Compare BridgeBio Pharma Inc (BBIO) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Kohl's Corporation — how do they compare? BridgeBio Pharma Inc trades at $82.33 (market cap $16.46B), while Kohl's Corporation trades at $17.17 (market cap $1.86B). The key difference: BridgeBio Pharma Inc is far larger — about 8.8× Kohl's Corporation's market cap, and Kohl's Corporation pays a 3.04% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | KSS | |
|---|---|---|
Market Cap | $16.46B | $1.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $24.71 |
52-Week Low | $44.81 | $9.27 |
Enterprise Value | $18.02B | $7.97B |
Dividend Yield | — | 3.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Kohl's (KSS) trades at $16.55, down 1.49% today, showing mixed signals with bearish technical indicators but attractive valuation metrics including a P/E of 6.95 and P/B of 0.47. Recent earnings have consistently beaten expectations, with Q1 2026 showing early turnaround progress despite revenue declines. The company maintains a 40.52% gross margin and positive cash flow from operations of $648M in 2025, while implementing strategic changes including new leadership appointments and proprietary brand expansion.
KSS presents a value opportunity with deep discount valuations, though facing significant headwinds from declining revenues and competitive pressures. The stock's near-term trajectory depends on successful execution of turnaround initiatives and proprietary brand growth, with analyst consensus at $16.75 offering modest upside potential from current levels amid cautious market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
